Understanding the Risks of ASX Small-Cap Stocks
Investing in small-cap stocks listed on the Australian Securities Exchange (ASX) can be both rewarding and risky. These companies often experience significant volatility due to limited liquidity, narrower customer bases, and greater sensitivity to market sentiment and economic changes. However, when brokers provide estimates of more than 300% upside potential, it’s worth considering the opportunities they present.
One such company is Saluda Medical Inc (ASX: SLD). This ASX small-cap healthcare stock has attracted attention due to its potential for substantial growth.
Company Overview
Saluda Medical is a commercial-stage medical device company that commercialises spinal cord stimulation (SCS) therapy. The company’s primary product is the ‘Evoke System’, a differentiated SCS solution designed for patients with chronic pain in the trunk and/or limbs.
Saluda has been commercialising the Evoke System for approximately three years in the US and around five years in Europe and Australia. As an ASX small-cap healthcare stock, Saluda has the potential for high upside due to factors such as successful clinical results, regulatory approvals, or commercial partnerships. However, these stocks are also more volatile because they often rely on future growth expectations, limited funding, and investor sentiment rather than stable earnings.
Despite the optimism surrounding Saluda, its share price has declined by 66% year to date, highlighting the risks associated with investing in small-cap stocks.
Bell Potter’s Optimistic Outlook
In the latest report from Bell Potter, the broker highlighted the size and growth of the US spinal cord stimulator market, which is valued at around US$2.3 billion and growing steadily. A major industry shift is towards “closed-loop” technology, which automatically adjusts stimulation levels. Bell Potter believes this is becoming the new standard in the industry.
While competitors already have closed-loop products, Bell Potter believes Saluda’s technology is stronger and is helping it grow quickly in the US market. Saluda’s recent growth rates have significantly outpaced the broader industry, leading Bell Potter to view the company as an emerging disruptor and a possible takeover target for larger competitors seeking faster growth.
With competitors without closed-loop technology at risk of being left behind, and Saluda offering the best available solution, the company is emerging as a formidable disruptor in the market.
Potential Upside and Market Traction
Based on Bell Potter’s guidance, the broker has retained its speculative buy recommendation and $2.00 price target on Saluda Medical. From last week’s closing price of 48 cents, this indicates an upside potential of 316%.
Saluda is gaining considerable commercial traction, with more than 150 US sales reps now on board. This suggests little reason to expect any slowdown in the quarters ahead.
Additional Considerations
Before investing in Saluda Medical shares, it’s important to consider various factors. Motley Fool investing expert Scott Phillips recently revealed what he believes are the 5 best stocks for investors to buy right now, and Saluda Medical was not among them.
The online investing service he runs, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled, or even more. Scott currently believes there are 5 stocks that may be better buys.
For further reading, you might explore topics such as whether Saluda Medical is the best buy on the ASX right now, Bell Potter’s view on the company following a clinical trial update, or other ASX healthcare shares that could triple in the next year.
Final Thoughts
Investing in small-cap stocks like Saluda Medical can offer significant upside potential, but it also comes with inherent risks. It’s essential to conduct thorough research and consider all factors before making an investment decision. While the potential for growth is enticing, the volatility of such stocks should not be overlooked. Always seek professional financial advice and make informed decisions based on your individual circumstances.
